...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Equity financing

it would appear that the equity financing will be for Zenith Capital Corp United States Subscribers

SUBSCRIPTION AGREEMENT FOR COMMON SHARES

TO:

Zenith Capital Corp. (the Corporation)

The undersigned (the Subscriber) hereby irrevocably subscribes for and agrees to purchase the number of common shares of the Corporation (Common Shares) set forth below for the aggregate subscription price set forth below (the Aggregate Subscription Price), representing a subscription price of US$2.50per Common Share (the “Subscription Price”), upon and subject to the terms and conditions set forth in the attached Terms and Conditions of Subscription for Common Shares of Zenith Capital Corp.(together with this page and the Schedules, the Subscription Agreement). By signing this Subscription Agreement, the Subscriber consents to the collection, use and disclosure of the Subscribers personal information in the manner described in Section 29 of this Subscription Agreement. In addition to this face page, the Subscriber must also complete the attached Schedules, as applicable.

Share
New Message
Please login to post a reply